KRAS mutations and lung cancer: Treatment and outlook

The KRAS gene provides instructions that help control cell growth and division. A mutation in this gene can result in excessive cell growth that can lead to cancer in the lungs, pancreas, or colon.

Treatment for KRAS-positive lung cancer can be challenging. However, advances in research are producing promising new therapeutic approaches.

This article looks at what KRAS-positive lung cancer is, and the diagnosis, treatment, and outlook for the disease.

In KRAS-positive lung cancer, the KRAS biomarker is present. This means that the KRAS gene, which produces a protein responsible for cell growth and division, has undergone a change that has resulted in excessive cell growth.

The KRAS biomarker occurs in about 15% to 25% of people who have non-small cell lung cancer (NSCLC), which is the most common type of lung cancer.

Researchers and healthcare professionals generally associate KRAS biomarkers with lung cancer that is often more difficult to treat than other types. However, new research developments and breakthroughs may offer promising new treatment options.

There are different types of KRAS-positive lung cancer that affect the amino acids in proteins in specific ways. The types include:

The most common form is G12C, which accounts for around 50% of all KRAS-positive lung cancer. This is currently the only type of KRAS-positive lung cancer that doctors are able to treat with targeted therapy.

According to the American Lung Association (ALA), a healthcare professional may determine if the KRAS biomarker is present in someone with lung cancer in the following ways:

The treatment for KRAS-positive lung cancer may differ between individuals. Health professionals will develop a treatment plan based on various factors, including the location and stage of the tumor.

Surgery to remove the cancer from the lung may be an option during the early stages of the disease, before it has spread to other areas of the body.

During the procedure, a surgeon will remove the tumor, some surrounding lung tissue, and often the nearby lymph nodes.

Chemotherapy uses medications to attack and destroy cancer cells.

Doctors may use chemotherapy in combination with other therapies as a first-line treatment for KRAS-positive lung cancer. However, the cancer can become resistant to the drugs, and they may become less effective over time.

Radiation therapy uses high-energy radiation beams to target and shrink or destroy cancer cells.

KRAS-positive lung cancer may sometimes be resistant to radiation therapy. Researchers believe this may occur when the KRAS mutation causes changes in other cells and their processes that prevent the treatment from being effective.

Immunotherapy is an effective treatment for many people with KRAS-positive lung cancer. Doctors have also found that a combination of immunotherapy and chemotherapy is effective for some people.

The treatment helps support a person’s own immune system to fight cancer cells.

Targeted therapy utilizes medications to identify and target specific proteins, genetic changes, or signals within cancer cells.

Targeted medications are available to treat people who have G12C KRAS-positive lung cancer, and scientists are attempting to develop new drugs to treat other types.

If a person’s G12C KRAS-positive lung cancer stops responding to immunotherapy and chemotherapy, a doctor may treat them with the targeted drugs adagrasib (Krazati) or sotorasib (Lumakras).

Scientists are developing and studying new types of medications and approaches for different forms of KRAS-positive lung cancer. These include azoldonrasib,a targeted therapy to treat KRAS G12D.

Researchers also believe that combining immunotherapy and targeted therapy may help KRAS-targeted drugs bind to the KRAS protein during a natural process in which cells break down proteins. This could help the immune system and targeted drugs identify and attack the cancer cells.

A team of healthcare professionals will work with a person to help them develop a treatment plan. A person’s treatment can depend on several factors, including the stage and location of the cancer and the person’s preferences and overall health.

A 2023 review of past research states that doctors have often linked KRAS gene changes to a worse outlook. However, research on this has been contradictory.

Some studies suggest that KRAS gene changes might not have a significant effect on the prognosis of NSCLC. Other studies suggest that certain KRAS gene types may have a more significant impact than others.

Scientists are still learning about how KRAS status affects lung cancer, its treatment, and survival rates. However, the overall 5-year relative survival rate for people with NSCLC between 2015 and 2021 was as follows:

5-year relative survival rates measure how many people of the same age survive for at least 5 years with cancer versus those without.

This data comes from several years ago, so people receiving diagnoses of lung cancer today may have a better outlook.

Below are answers to some common questions about KRAS-positive lung cancer.

It may be possible for doctors to cure KRAS-positive lung cancer in some cases. Treatment is more likely to be successful with early diagnosis.

It may be possible for doctors to cure KRAS-positive lung cancer in some cases. Treatment is more likely to be successful with early diagnosis.

KRAS-positive cancer may respond to chemotherapy, especially in combination with immunotherapy. However, the disease may become drug-resistant, and a person may require different treatments.

KRAS-positive cancer may respond to chemotherapy, especially in combination with immunotherapy. However, the disease may become drug-resistant, and a person may require different treatments.

KRAS-positive lung cancer is hard to target because the structure of the KRAS protein makes it difficult for drugs to bind to. KRAS-positive cancers may also involve complex changes in other genes and cells.

KRAS-positive lung cancer is hard to target because the structure of the KRAS protein makes it difficult for drugs to bind to. KRAS-positive cancers may also involve complex changes in other genes and cells.

KRAS-positive lung cancer involves a mutation in the KRAS gene. This biomarker is present in about 25% of people with the most common type of lung cancer, NSCLC.

KRAS-positive lung cancer can become drug-resistant, which makes it difficult to treat. A healthcare team may develop a treatment plan that includes surgery, chemotherapy, radiation therapy, immunotherapy, and sometimes targeted therapy.

Scientists are developing and studying promising new therapies that may help treat various types of KRAS-positive cancers in the future.